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Abstract: (1) Background: Carpal tunnel syndrome (CTS) is the most common peripheral neuropathy
in the upper extremity. Conservative treatment has been effective for mild and moderate idiopathic
CTS. However, severe CTS and systemic conditions were an exclusion criterion from the studies.
The aim of this study is to review the effectiveness of conservative treatment in patients with CTS
regardless of the level of severity and the presence or not of systemic diseases in the last ten years. (2)
Methods: Randomized controlled clinical trials that compared the effect of conservative treatment on
the Boston questionnaire and pain were selected. PubMed, PEDro, Scopus, Cochrane, and Web of
Science databases were used. PRISMA statement checklist was performed. (3) Results: 876 studies
were recorded, 29 were selected. Pharmacology, Electrotherapy and Manual Therapy had benefits
for CTS. Electrotherapy and manual therapy could be effective for severe CTS patients with a
systemic condition in the short term, but there was a low percentage of these patients included in
the studies. (4) Conclusion: Some pharmacological treatments, manual therapy and electrotherapy
have shown benefits for handling CTS, although the most effective combination of techniques is
unknown. It would be necessary to include patients with systemic conditions in the selection criteria
for future studies.
Keywords: carpal tunnel syndrome; conservative treatment; diabetic neuropathy; electric stimulation
therapy; musculoskeletal manipulation; pain
1. Introduction
Carpal tunnel syndrome (CTS) is defined as an entrapment of the median nerve in the
carpal tunnel in the wrist, generally associated with an increase in carpal tunnel pressure [1].
It is the most common peripheral neuropathy in the upper quadrant. The prevalence for
CTS ranges from 3.8% to 4.9%, with women being three times more predisposed than
men [1,2]. The elevated prevalence of this pathology causes annual healthcare costs to rise,
increasing the socioeconomic costs [3].
CTS is characterized by pain and paresthesia in the distributions of the median nerve,
including the palmar side of the first finger, the second and third finger and the radial half
Int. J. Environ. Res. Public Health 2021, 18, 2365. https://doi.org/10.3390/ijerph18052365 https://www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2021, 18, 2365 2 of 34
of the fourth finger; it also involves a loss of sensitivity, manual dexterity and functionality.
However, the signs and symptoms vary and do not correlate with the level of severity [1,4].
In severe cases, weakness of median nerve innervated muscles and spreading symptoms
to the forearm, upper arm and sometimes to shoulder could be described. Atrophy of the
thenar eminence and weakness of thumb abduction and opposition seem to be the most
significant signs [1,5].
Some clinical conditions such as obesity, diabetes and hypothyroidism are linked to
a double risk of developing CTS, due to the increased intraneural pressure in the carpal
tunnel or vascular deficiencies [6–8]. Different mechanisms have been hypothesized:
impaired microvascular circulation for diabetes type 1 and 2 [9]; mucopolysaccharide
complex depot for thyroid diseases [10]; hormonal alteration and oedema for menopause
and pregnancy [5]; alteration of the fluid balance in the body for obesity [11]. However,
more investigation should be done to prove those mechanisms.
In clinical practice guidelines, conservative treatment is recommended for mild and
moderate cases, while a surgical approach is recommended for patients with severe
CTS [4]. When dealing with patients having severe CTS without diabetic neuropathy,
based on thenar muscle atrophy and electrophysiological findings, surgical release is rec-
ommended [4]. Even if the results of surgical intervention (carpal tunnel release) are
predictable to some extent: about 80–90% of patients have good to excellent long-term
outcomes, remaining 10–20% have less satisfactory (suboptimal) outcomes, and some of
them poor outcome [12]. However, severe symptoms could be present without electrophys-
iological abnormalities. In a systematic review [13], the effectiveness of the conservative
treatment in patients with mild and/or moderate CTS was showed. The use of manual
therapy, electrotherapy and pharmacological treatments (the most common techniques
nowadays) was described, but no conclusion was given as to which of them was more
effective. Other systematic review shows that conservative treatment is effective for short
terms but not to longer terms and finally resorting to surgical intervention [14]. These types
of treatment were reviewed with the exclusion of patients having severe intensity and/or
systemic pathology, conditions that are usually a criterion for exclusion in the sample
selection. However, the CTS prevalence in patients with diabetes ranges from 14% in
subjects without diabetic neuropathy, up to 30% in patients with diabetic neuropathy [15],
with a 84% of risk from suffering CTS during their lifetimes [7]. In addition, even if patients
with diabetic neuropathy may improve function and symptoms after CTS surgical release,
these subgroup of patients have worst results than CTS patients without this condition [16].
Moreover, they suffer from more complications arising from those procedures. These
aspects should be taken into account for treatment election [5,9] for this type of patients
and conservative approach could be considered.
We decided to carry out this systematic review because less attention is given to the
conservative approach in patients with severe CTS and systemic diseases, there is elevated
incidence and prevalence of systemic pathology in CTS, and the fact that CTS involves
high individual and socioeconomic costs.
The aim of this study was to review the effectiveness of the conservative treatment in
patients having CTS, including severe CTS and patients with systematic diseases in the last
10 years.
2. Materials and Methods
2.1. Protocol and Register
A systematic review based on the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement checklist [17] was designed. The systematic review
was registered on the Open Science Framework digital platform: https://osf.io/45q28/
(accessed date 17 February 2021) (DOI 10.17605/OSF.IO/45Q28).
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2.2. Information Sources and Search
To create an accurate search strategy, the PICOS (Population, Intervention, Compar-
ison, Outcome and Study design) strategy was taken into account. The Population was
people suffering from CTS; the Intervention was conservative treatment such as manual
therapy, exercise, electrotherapy or pharmacology; the Comparison was Control, Placebo
or other therapies; the Outcome was pain and function; and the Study Design was Random-
ized Controlled Trial. The following databases were searched: PubMed, Physiotherapy
Evidence Database (PEDro), Cochrane Library, SCOPUS and Web of Science. The MESH
terms used were “Carpal Tunnel Syndrome”, “Therapy”; “Manual Therapy”; “Neural
Mobilization” and “Treatment Outcome”. Common filters used were language, document
type and years. Different search strategies were performed for each database, according to
their own filters. The search in PEDro was more concise than the others due to its search
method. Boolean operators were used to limit or enlarge the strategy research. Boolean
“OR” was used to enlarge the search strategy linking similar terms. Boolean “AND” was
used to connect different terms that should be included in search studies in order to limit
the search strategy. Table 1 shows the search strategy from each database. The search was
performed for dates between 6 September–2 October 2020.
Table 1. Search Strategy.
Database Search Strategy Filters
PubMed
“Carpal Tunnel Syndrome” AND (Therapy OR
“Physical Therapy” OR “Manual Therapy” OR
“Neural mobilization”) AND Treatment outcome
Text availability: Full text.
Article type: Clinical Trial;
Randomized Controlled Trial.
Publication date: 10 years.
Language: English, Spanish, French.
Web of Science
“Carpal Tunnel Syndrome” AND (Therapy OR
“Physical Therapy” OR “Manual Therapy” OR
“Neural mobilization”) AND Treatment outcome
Document type: Article
Timespan: 2010 to 2020
SCOPUS
“Carpal Tunnel Syndrome” AND (Therapy OR
“Physical Therapy” OR “Manual Therapy” OR
“Neural mobilization”) AND Treatment outcome
Document type: Article
Years: 2010–2020
Language: English, Spanish, French
Cochrane Library
“Carpal Tunnel Syndrome” AND (Therapy OR
“Physical Therapy” OR “Manual Therapy” OR
“Neural mobilization”) AND Treatment outcome
Years: 2010–2020
Trials
Language: English, Spanish, French
PEDro “Carpal Tunnel Syndrome” “Therapy”
Published since: 2010.
When searching: Match all search terms (AND).
Method: Clinical Trial.
2.3. Eligibility Criteria
The selection of articles included all studies published since 2010 that fulfilled the
following criteria: 1. Randomized controlled clinical trials that compared a conservative
treatment group with a control group, a placebo group or a group that received a strictly
different treatment; 2. studies in which the sample included patients diagnosed with
idiopathic-type CTS with or without systemic pathology; 3. studies including pain and
functional variables; 4. studies that evaluated a functional item using the Boston Carpal
Tunnel Questionnaire (BCQT), a tool with standardized, patient-based results for the
seriousness of the symptoms and the functional status in patients with CTS [18]; 5. studies
having a score equal to or more than 6 in the PEDro Scale; 6. studies published in English,
French or Spanish.
We excluded the studies in which the sample included the following criteria: 1. preg-
nant women; 2. patients having suffered traumatisms in the cervical area or upper extremity
that might contribute to CTS and its symptoms; 3. subject with previous surgery and/or
surgery during the study period as a CTS treatment.
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2.4. Study Selection
Eligible articles and data extraction were conducted independently by two authors
(M.H.S. and R.M.C.). Firstly, they evaluated titles and abstracts following the criteria for
eligibility, and then complete texts. For any discrepancies or doubts, a third author (C.H.G.)
was consulted to resolve the discrepancy.
2.5. Data Extraction Process
The following information was extracted for each study: (1) variables analyzed; (5)
follow-ups; and (6) results.
2.6. Risk of Bias in the Individual Studies
To assess the methodological quality of the clinical trials, the PEDro scale and the Risk
of Bias 2 (RoB2) tool in the Cochrane database were used.
The PEDro scale is based on the Delphi list, based on an expert consensus, to help the
reader to identify the clinical trials with sufficient internal validity and sufficient statistical
information to make their results interpretable. It is formed by 11 criteria to answer using a
“Yes” or “No” response, as long as the information is clearly expressed in the study. Each
criterion is given 1 point, and the maximum score is 11 points [19].
The RoB2 tool is the second version of the Cochrane tool to assess the risk of bias
in clinical trials. The biases are evaluated in 5 domains: (1) randomization process; (2)
effect of being assigned to intervention; (3) missing outcome data; (4) measurement of the
outcome; (5) reported results. Within each domain, 1 or more questions must be answered.




The literature search yielded 876 articles (PubMed: 155, Web of Science: 109; Scopus:
313; PEDro: 62; Cochrane: 237). After we eliminated the duplicated studies, 226 articles
were selected for further analysis.
The first analysis focused on the study title and the abstract. We excluded 115 articles
because of the study design, sample, presence of surgical intervention, lack of complete
article or language different from those of the inclusion criteria.
The last step was analyzing the remaining 111 complete articles to select the ones that
fulfilled the inclusion criteria, being finally selected 29 articles for analysis. The selection
process is shown in the flow diagram (Figure 1).
3.2. Study Characteristics
3.2.1. Sample
The study characteristics are presented in Tables 2–4. All the articles offered a sample
of 1780 upper limbs with CTS. Of these, 28 articles assessed patients with idiopathic CTS,
2 also assessed patients with hypertension and diabetes [21,22] and only 1 article assessed
strictly diabetic patients [23]. Additionally, all the studies include mild and moderate
severity of CTS, and 8 studies included severe CTS patients [22–29].
To diagnose the presence of CTS and classify the intensity level of the CTS syndrome,
most of studies performed an electrophysiological study. However, three of them did not
include any neurological study, using only physical examination [25,30,31]. Mostly, the
physical examination consisted of the presence of symptoms such as paresthesia and pain
in median nerve distribution area, positive Phalen’s and Tinel’s test. Others test performed
was Katz’s diagram and the flick sign. The Guideline of the American Academy of Neurol-
ogy (AAN) was used to classify CTS severity according to neurophysiological findings.
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Figure 1. Flow Diagram.
3.2.2. Intervention
Six studies observed the effectiveness of drugs [29,32–36]; eight studies evaluated the
effectiveness of electrotherapy [21,22,25,37–41] (diathermy, shock waves, radiofrequency,
and so on); and eight studies the effect of manual therapy [26–28,42–46]. Three studies
compared electrotherapy and a drug intervention [24,47,48] and two studies compared
electrotherapy and manual therapy [23,30]. Two articles differed from these categories:
one study analyzed the effectiveness of an alternative therapy (lavender ointment) [49]
and the other one, a thermal agent (paraffin wax) [50]. Twelve studies had a control
group [22,25,27,28,33,41–46]; nine studies a placebo group [21,29,37–40,42,48,49]; and thir-
teen studie an alternative treatment [23,24,26,27,30,32,34–37,39,47,48]. There were six
articles having three or more groups [27,32,37,39,42,48].
Applying a splint, applied during night and/or day, was generally the control treat-
ment of choice. Th material of the splint was neopre e or a thermoplastic tissue. Some
studies provided costumed or prefabricated splints, without describing the kind of material,
except for studies that used kinesiotaping. The wrist was placed in neutral position, but
this position was only described in two studies (0–5 degrees of wrist extension) [33,44]. The
educational instruction to explain how to use the splint was considered in a few studies.
Only one study combined basic medical care such as ibuprofen with splint treatment [44].
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Table 2. Characteristics of Studies: Mild and Moderate CTS.
Study
Sample
Groups Outcomes Follow-ups Results





G1: Continuous ultrasound continuo
(10 sessions × 10 min) + Night splint
(2 wks)
G2: Pulsed ultrasound (10 sessions ×
10 min) + Night splint (2 wks)
G3: Placebo (Ultrasound–10 sessions
× 10 min) + Night splint (2 wks)




0, 2, 6 weeks
G1: Improvement in all parameters at 2 and
6 wks [<0167]
G2: Improvement in all parameters at 2 and
6 wks [<0167]
G3: Improvement in all parameters at 2 and
6 wks [<0167] except for grip strength at 6





G1: Unciform and scaphoid bone
mobilization (10 min, 3 v/wk × 8
wks) + Night splint (8 wks)
G2: Control (Night splint—8 wks)




G1: Improvement in BCTQ and VAS [<05];
DSL y DML [<05].
G2: Improvement in BCTQ and VAS [<05];
DSL y DML [<05].






G1: Lavender ointment (2 times/day
× 40 days) + Night splint (40 d)
G2: Placebo (ointment 2 times/day ×





G1: Improvement in BCTQ, VAS, pinch and
grip strength [05].
G2: Improvement in BCTQ, VAS, pinch and
grip strength [05].






G1: Diode laser (15 sessions × 5 wks,
3 times/wk) + Splint (12 wks
morning and night)
G2: Placebo (Laser–15 sessions x 5







0, 5 and 12 weeks
G1: Improvement in VAS, BCTQ and grip
strength at 5 and 12 wks [05]; Pinch
strength and DML at 12 wks [05].
G2: Improvement in VAS and BCTQ at 5
and 12 wks [05]. Pinch strength and DML
at 12 wks [05]
G1 vs. G2: Improvement in BCTQ-SSS at 5
wks [031].




Groups Outcomes Follow-ups Results





G1: Kinesio-tape (1 time/5 days with
2d rest) + Gliding exercises (4 wks)
G2: Placebo (kinesio-tape–1 time/5
days with 2 days of rest) + Gliding
exercises (4 wks)
G3: Night splint (as often as possible)





G1: Improvement in VAS, DN4, BCTQ
[001].
G2: Improvement in VAS, DN4, BCTQ-SSS
[001].
G3: Improvement in VAS, DN4, grip
strength, BCTQ-SSS [001].
G1 vs. G3: Significant difference in favour







G1: Carpal bone mobilization (10









G1: Improvement in all clinical variables
[<022]. DSL y SNAP [05].
G2: Improvement in BCTQ-SSS and NPRS
[01].
G1 vs. G2: Greatest improvement in G1







G1: Low-intensity laser (5 times/wk
× 3 wks × 12 min)
G2: Low intensity laser (5 times/wk
× 3 wks × 12 min) + Kinesio-tape
(changed every 2d)
G3: Placebo (Laser—5 times/wk × 3





0, 3, 12 weeks
G1: Improvement in VAS, BCTQ, pinch
strength at 3 and 12 wks [05]; Grip strength
at 3 wks [014]; MA and SNCV at 12 wks
[05].
G2: Improvement in VAS, BCTQ, pinch and
grip strength at 3 and 12 wks [05]; MA, DSL
and SNCV at12 wks [05].
G3: Improvement in VAS and BCTQ (SSS) 3
wks [05]; DSL and SNCV at 12 wks [05].
G1 vs. G2: Greatest improvement in pinch
and grip strength at 12 wks [<03] in G2.
G1 vs. G3: Greatest Improvement in VAS
and BCTQ at 3 and 12 wks [<01]; Grip
strength at 3 wks [028] in G1.
G2 vs. G3: All parameters at all times [<03]
in G2.




Groups Outcomes Follow-ups Results







G1: Acupuncture (2 times/wk × 4
wks) + Night splint
G2: Control (Night splint+
Ibuprofen–3 times/day × 10 d)
BCTQ, VAS (pain),
DSL, DML, SNCV. 0, 4 weeks
G1: Improvement in VAS, BCTQ, DSL,
DML, SNCV [<001]
G2: Improvement in VAS, BCTQ, DSL,
DML, SNCV [<001]
G1 vs. G2: Improvement in VAS [<001],







G1: Short wave diathermy (15 min ×
5 times/wk × 3 wks) + Gliding
exercises
G2: Placebo (diathermy off–15 min ×
5 times/wk × 3 wks) + Gliding
exercises
VAS (pain), BCTQ,
clinical parameters. 0, 3 weeks
G1: Improvement in all variables [<001]
G2: No improvement.








G1: 20 mg Triamcinolone
G2: 40 mg Triamcinolone
G3: 20 mg Methylprednisolone





G1: Improvement in all variables [<026]
except CMAP.
G2: Improvement in all variables [<034].
G3: Improvement in all variables [<017]
except grip strength y CMAP.
G4: Improvements in all variables [<01]
except CMAP.
G1 vs. G2 vs. G3 vs. G4: Significant
difference only in amount in BCTQ-FSS







G1: Electro-acupuncture (2 times/wk
× 5 wks)
G2: Control (Night splint—5 wks)
BCTQ, VAS (pain) 0, 5 weeks
G1: Improvement in all variables [<05].
G2: Improvement in BCTQ-SSS [008].
G1 vs: G2: Significant improvement in VAS
[028] in G1.




Groups Outcomes Follow-ups Results







G1: Paraffin (5 days/wk × 3 wks) +
Splint (always for 3 wks) + Exercises
(2 times/day)
G2: Control (Splint (always for 3 wks)





G1: Improvement in all variables [<03]
except CMAP.
G2: Improvement in VAS y BCTQ-SSS
[<02].
G1 vs. G2: Significant improvement









plasma (1 injection) + Night splint (8
wks)
G2: Control (Night splint—8 wks)
BCTQ, VAS (pain),
SNAP, CMAP 0, 10 weeks
G1: Improvement in all variables [<01]
except CMAP.
G2: Improvement in all variables [<01].







G1: Platelet-rich plasma (1 dose)
G2: 1ml methylprednisolone acetate
(1 dose)
BCTQ, VAS (pain and
paraesthesia), Phalen,
Tinel, DML, CMAP, SL,
SNAP, CSA.
0, 1 and 3 months
G1: Improvement in all variables [<01] at
all follow-ups.
G2: Improvement in the variables [<01] at
all follow-ups.
G1 vs. G2: No significant differences a 1 m.
Significant improvement to 3 m in
VAS-pain [041]; VAS-paraesthesia [040];
Phalen [041]; Tinel [039], BCTQ-SSS [007];








G1: Triamcinolone + lidocaine (1
ultrasound-guided dose) + Splint (as
often as possible for 12 wks)





0, 6, 12 weeks
G1: Improvement in all variables except
CMAP [<001] 6 and 12 wks.
G2: Improvement in all variables except
CMAP [<05] 6 and 12 wks.
G1 vs. G2: Significant improvement at 12
wks in BCTQ-SSS [0032], BCTQ-FSS [.019]
SNCV [015], SNAP [025] in G1.




Groups Outcomes Follow-ups Results







G1: Neurodynamic techniques (20







G1 vs. G2: Significant improvement SNCV
[<01], MT [<01], NPRS [<01], BCTQ-SSS







G1: Neurodynamic techniques +
Function massage + Joint
mobilization (15 × 2 times/wk × 10
wks).
G2: Laser + ultrasound (15 × 2
times/wk × 10 wks).
BCTQ, VAS (pain),
SNCV, MNCV, MT, SL 0, 10 weeks
G1: Improvement in all variables [<01]
G2: Improvement in all variables [<05]
except SNCV and MNCV.
G1 vs. G2: Significant improvement in VAS








G1: 5mL Dextrose (1 dose)
G2: 3mL Triamcinolone
VAS (pain), BCTQ,
CSA, SNCV, DML. 0, 1, 3, 4, 6 months
G1: Improvement in all variables at all
times [<03] except DML at 1 and 6 months.
G2: Improvement in VAS, BCTQ-SSS,
BCTQ-FSS n 1, 3, 4 m [<01] and VAS 6 m
[<001]
G1 vs. G2: Significant improvement VAS at
4 m [<01] and 6 m [<001]; BCTQ-SSS at 4 m
[<01] and 6 m [<001] and BCTQ-FSS at 4 m







G1: Perineural injection of 5%
dextrose (1 dose)
G2: Placebo (1 dose of perineural
injection with saline)
VAS (pain), BCTQ,
CSA, SNCV, DML. 0, 1, 3, 6 months
G1: Improvement in all variables at all
times [<05] except DML.
G2: Improvement in VAS, BCTQ-SSS,
BCTQ-FSS (not at 1 month) and CSA at all
times [<05]
G1 vs. G2: Significant improvement in VAS
1m [<01], 3m [<05], 6m [<001]; BCTQ-SSS
1m [<05], 3m [<.05], 6m [<.001]; BCTQ-FSS
1 m [<001], 3 m [<001], 6 m [<001]; SNC 1 m
[03], 3 m [001], 6 m [006]; DML 1 m [04], 3
m [03]; CSA 3 m [01], 6 m [004].




Groups Outcomes Follow-ups Results







G1: Radial extracorporeal shock
waves (1 time/wk × 3 wks)




0, 3, 9 and 12 weeks
G1: Improvement in VAS, BCTQ, SNAPdl
and CMAPdl 12 wks [<05]; VAS, BCTQ and
SNAPdl 9 wks [<05]; VAS and BCTQ 3 wks
[<05].
G2: Improvement in VAS and BCTQ 3 wks
[05]; BCTQ 9 wks [05].
G1 vs. G2: Significant improvement VAS 9
wks [<001], 12 wks [<001]; BCTQ 9 wks








G1: Ultrasound + Gel with ketoprofen
(15 min × 5 times/wk × 2 wks) +
Splint (8 wks)
G2: Ultrasound + Gel with drugs (15
min × 5 times/wk × 2 wks) + Splint
(8 wks)
G3: Placebo (ultrasound off + gel
without drugs) (15 min × 5 times/wk
× 2 wks) + Splint (8 wks)
VAS (pain), BCTQ 0, 2 and 8 weeks
G1: Improvement in all variables 2 and 8
wks.
G2: Improvement in all variables 2 and 8
wks.
G3: Improvement in all variables 2 and 8
wks.
G1 vs. G2: Significant improvement in VAS
8 wks [004] in G1.
G1 vs. G3: Significant improvement in VAS
8 wks [002] in G1.
G2 vs. G3: No significant differences.
BCTQ: Boston Carpal Tunnel Questionnaire; BCTQ-SSS: BCTQ Symptom Severity Scale; BCTQ-FSS: BCTQ Function Severity Scale; CMAP: compound muscle action potential; CMAPa: CMAP amplitude;
CMAPdl: CMAP distal latency; CSA: cross-sectional area; DASH: Disability of Arm, Shoulder and Hand questionnaire; DML: distal motor latency; DSL: distal sensitivity latency; EMG: electromyography; F:
female; M: male; m: month(s); MA: motor amplitude; min: minutes; MNCV: motor nerve conduction velocity; MT: motor latency; NPRS: Numeric Pain Rating Scale; SA: sensory amplitude; SL: sensory latency;
SNAP: sensory.nerve action potential; SNAPa: SNAP amplitude; SNAPdl: SNAP distal latency; SNCV: sensory nerve conduction velocity; TNDM: test of neurodynamic median nerve mobilization; VAS: visual
analogue scale; wk(s): week(s).
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Table 3. Characteristics of Studies: Studies Including Severe and Systemic Condition.
Study
Sample
Groups Outcomes Follow-ups Results







G1: Radial extracorporeal shock waves
(3–7 min + 15 min cold)





0, 1, 4, 12 and 24
weeks
G1: Improvement in VAS at 12 and 24 wks
[05], BCTQ at 4 [05], 12 and 24 wks [01]; DSL
at 12 wks [01].
G2: Improvement in BCTQ at 1 and 4 wks
[01]; DSL 12 wks [01].
G1 vs. G2: Improvement in BCQT at 12 a 24







G1: Pulsed radiofrequency (32 min) +
Night splint (8 h)




0, 1, 4, 8, 12 weeks
G1 vs. G2: All parameters following
intervention [<05]. Greatest improvement in
VAS and BCTQ at all times, except BCTQ-SSS,







G1: Electro-acupuncture (13 sessions ×
20 min) + 8 h Night splint





0, 1, 2, 5, 17 weeks
G1 vs. G2: Improvement in BCTQ-FSS and
DASH [05] at 1 and 17 wks. Improvement in







G1: Neurodynamic technique with
exercises to do at home (1 h × 1 time/wk
× 4 wks)
G2: Exercise programme (1h × 1time/wk




0, 1, 6 months
G1: Improvement in BCTQ, NPRS, DASH,
RDM, grip strength [<05]
G2: Improvement in BCTQ, NPRS, DASH,
RDM [<05]
G1 vs. G2: Improvement in BCTQ-FSS [.004],







G1: Tendon gliding exercises (3
times/day) + Paraffin (2 times/wk) +
Night splint (8 wks)
G2: Nerve gliding exercises (3 times/day)
+ Paraffin (2 times/wk) + Night splint (8
wks)






G1: Improvement in BCTQ, VAS, DASH,
WHOQOL (2 domains) [05].
G2: Improvement in BCTQ-SSS, VAS,
WHOQOL (1 domain) [05].
G3: Improvement in BCTQ-SSS, VAS,
WHOQOL (1 domain) [05].
G1 vs. G2 vs. G3: Significant improvement in
BCTQ-FSS in G1 [04]




Groups Outcomes Follow-ups Results







G1: Manual therapy–Nerve + interface
mobilization + neural (25 min × 3
times/wk × 4 wks)
G2: TENS (20 min) + Ultrasound (5 min)
(3 times/wk × 4 wks)
VAS (pain), BCTQ,
TNDM test. 0, 4 weeks
G1: Improvement in all variables [<009]
G2: Improvement in VAS and BCTQ-SSS
[<001]
G1 vs. G2: Significant improvement in








G1: Acupuncture (2 times/wk x 5 wks) +
Night splint
G2: Control (Night splint)













G1: Radial extracorporeal shock waves +
Splint





1, 4, 8 and 12 weeks
G1: Improvement in all variables at all times
[<01] except SNCV 1 wk.
G2: Improvement in all variables at all times
[<05] except BCTQ-FSS 8 wks and 12 wks.
G1 vs. G2: Significant improvement in VAS
at 1 wk [<001], 4 wks [<001], 8 wks [003], 12
wks [006]; BCTQ-SSS at 1 wk [017], 4 wks
[005], 8 wks [008]; BCTQ-FSS at 1 wk [001], 4
wks [002], 8 wks [002], 12 wks [007]; CSA at 1
wk [07], 8 wks [041], 12 wks [043] in G1.
BCTQ: Boston Carpal Tunnel Questionnaire; BCTQ-SSS: BCTQ Symptom Severity Scale; BCTQ-FSS: BCTQ Function Severity Scale; CMAP: compound muscle action potential; CMAPa: CMAP amplitude;
CMAPdl: CMAP distal latency; CSA: cross-sectional area; DASH: Disability of Arm, Shoulder and Hand questionnaire; DML: distal motor latency; DSL: distal sensitivity latency; EMG: electromyography; F:
female; M: male; m: month(s); MA: motor amplitude; min: minutes; MNCV: motor nerve conduction velocity; MT: motor latency; NPRS: Numeric Pain Rating Scale; SA: sensory amplitude; SL: sensory latency;
SNAP: sensory nerve action potential; SNAPa: SNAP amplitude; SNAPdl: SNAP distal latency; SNCV: sensory nerve conduction velocity; TNDM: test of neurodynamic median nerve mobilization; VAS: visual
analogue scale; WHOQOL: Word Health Organization (WHO) Quality Of Life scale; wk(s): week(s).
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Table 4. Pain and BCTQ Results of Studies.

















G1. Pre (5.4 ± 2.4) vs. Post (4 ± 1.8) p = 0.007
G2. Pre (5.4 ± 2.4) vs. Post (3.7 ± 2.2) p =
0.001
G3. Pre (5.6 ± 1.8) vs. Post (4.1 ± 1.9) p =
0.014




3.84 ± 2.1 vs. 3.53
± 2.1 (p = 0.53)
20 mg vs. 40 mg
4.05 ± 1.8 vs. 3.36
± 2.2 (p = 0.14)
G1. Pre (32.5 ± 11.8) vs. Post (24.9 ± 10.2) p
= 0.002
G2. Pre (31.7 ± 8.6) vs. Post (22.3 ± 1.1) p =
0.001
G3. Pre (31.9 ± 8) vs. Post (.1 ± 1.9) p =
0.001
G4. Pre (5.3 ± 2.9) vs. Post (3 ± 2.2) p =
0.001
Triamcinolone vs. Methylprednisolone
23.5 ± 10.5 vs. 22.6 ± 7.7 (p = 0.67)
20 mg vs. 40 mg
23.88 ± 9.3 vs. 22.44 ± 9.1 (p = 0.50)
G1. Pre (32.5 ± 11.8) vs. Post (24.9 ± 10.2)
p = 0.002
G2. Pre (31.7 ± 8.6) vs. Post (22.3 ± 1.1) p
= 0.001
G3. Pre (31.9 ± 8) vs. Post (.1 ± 1.9) p =
0.001
G4. Pre (5.3 ± 2.9) vs. Post (3 ± 2.2) p =
0.002
Triamcinolone vs. Methylprednisolone
14.0 ± 4.9 vs. 15.3 ± 5.3 (p = 0.27)
20 mg vs. 40 mg










G1. Pre (6.82 ± 1.24) vs. Post (4.02 ± 1.92) p < 0.001
G2. Pre (6.24 ± 1.13) vs. Post (3.52 ± 2.02) p < 0.001
G1 vs. G2–2.90 ± 2.1 vs. -2.76 ± 2.4 (p = 0.845; Power = 0.073; p =
0.098 adjusted for age).
G1. Pre (2.43 ± 0.73) vs. Post (17 ± 0.52) p <
0.001
G2. Pre (2.76 ± 0.40) vs. Post (1.90 ± 0.42) p
< 0.001
G1 vs. G2. -0.05 ± 0.2 vs. −0.19 ± 0.4 (p =
0.174; Power = 0.393; p = 0.194 adjusted for
age).
G1. Pre (2.54 ± 0.63) vs. Post (1.82 ± 0.42)
p < 0.001
G2. Pre (2.36 ± 0.83) vs. Post (1.83 ± 0.73)
p < 0.001
G1 vs. G2 −0.86 ± 0.5 vs. −0.63 ± 0.8 (p









G1 (F = 150,217;
p < 0.001)





G2 (F = 116,217; p < 0.001)
Pre: 69.5 ± 4.9
1 month: 25.9 ± 8.3
3 months: 25.2 ± 7.1
G1 vs. G2
Pre: t = 1.178; p =
0.242
1 month: t =
0.337; p = 0.737
3 months: t =
2.100; p = 0.040
G1 (F= 94,739; p < 0.001)
Pre: 3.5 ± 0.4
1 month: 2.4 ± 0.6



















G2 (F = 71,821; p < 0.001)
Pre: 3.4 ± 0.5
1 month: 3.0 ± 0.4
3 months: 2.5 ± 0.6
G1 vs. G2
Pre: t = 1.1082; p = 0.274
1 month: t = 0.268; p = 0.790
3 months: t = 2.752; p = 0.007
G1 vs. G2
Pre: t = 1.282; p = 0.204
1 month: t = 1.283; p = 0.203
3 months: t = 1.385; p = 0.002
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Pre: 3.61 ± 3.27





Pre: 2.23 ± 2.59
6 weeks: 0.40 ± 0.84
12 weeks: 0.80 ± 1.57
G1 vs. G2
6 weeks: 0.40
(–0.45 to 1.25) p =
0.993
12 weeks: 0.19
(−0.82 to 1.21) p
= 0.898
G1
Pre: 2.27 ± 0.71
6 weeks: 1.30 ± 0.53
















Pre: 1.61 ± 0.62
6 weeks: 1.18 ± 0.28
12 weeks: 1.32 ± 0.35
G1 vs. G2
6 weeks: 0.02 (−0.20 to 0.24) p = 0.216
12 weeks: -0.17 (-0.43 to 0.09) p = 0.246
G1 vs. G2
6 weeks: 0.14 (−0.10 to 0.40) p = 0.654










Pre: 6.67 ± 0.30
1 month: 4.60
± 0.35 (p <
0.001)
3 months: 3.57
± 0.30 (p <
0.001)
6 months: 2.43
± 0.30 (p <
0.001)
G2
Pre: 6.56 ± 0.30
1 month: 5.64 ± 0.35 (p =
0.002)
3 months: 4.70 ± 0.46 (p <
0.001)
6 months: 4.59 ± 0.46 (p <
0.001)
G1 vs. G2
1 month: −2.07 ±
0.24 vs. −0.93 ±
0.21 (p = 0.001)
3 months: −3.10
± 0.35 vs. −1.86
± 0.37 (p = 02)
6 months: −4.23
± 0.33 vs. −1.98
± 0.37 (p < 0.001)
G1
Pre: 30.20 ± 1.25
1 month: 20.83 ± 1.06 (p <
0.001)
3 months: 17.60 ± 0.80 (p <
0.001)

































Pre: 19.93 ± 0.96
1 month: 18.00 ± 1.05 (p =
09)
3 months: 16.77 ± 1.18 (p
= 0.005)
6 months: 17.07 ± 1.23 (p
= 03)
G1 vs. G2
1 month: −9.37 ± 1.20 vs. -5.70 ± 0.93 (p =
0.02)
3 months: −12.60 ± 1.19 vs. -7.57 ± 1.54 (p
= 0.01)
6 months: -14.90 ± 1.24 vs. −6.47 ± 1.46 (p
<0.001)
G1 vs. G2
1 month: −7.70 ± 0.97 vs. −1.93 ± 0.65 (p
< 0.001)
3 months: −8.97 ± 0.73 vs. −3.17 ± 0.79
(p < 0.001)
6 months: −10.43 ± 0.83 vs. -2.87 ± 0.86
(p < 0.001)
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Pre: 6.3 ± 0.3
1 month: 4.2 ± 0.3;
−2.1 (−1.4 to −2.8)
(p < 0.001)
3 months: 3.3 ± 0.2
−3.1 (−2.2 to −3.9)
(p < 0.001)
4 months: 2.8 ± 0.3
−3.6 (−2.6 to −4.5)
(p < 0.001)
6 months: 2.0 ± 0.3
−4.3 (−3.2 to −5.4)
(p < 0.001)
G2
Pre: 6.2 ± 0.2
1 month: 4.2 ± 0.4
−2.1 (−1.0 to −3.2)
(p ≤ 0.001)
3 months: 3.57 ± 0.30
−2.6 (−1.7 to −3.5)
(p < 0.001)
4 months: 3.57 ± 0.30
−2.3 (−1.4 to −3.3)
(p < 0.001)
6 months: 2.43 ± 0.30
−1.7 (−0.7 to −2.7)
(p < 0.001)
G1 vs. G2
1 month: (p >
05)
3 months: (p >
05)
4 months (p <
01)
6 months (p >
001)
G1
Pre: 28.2 ± 1.2
1 month: 19.8 ± 0.9;
−8.4 (−4.5 to −12.4) (p <
0.001)
3 months: 16.4 ± 0.7;
−3.1 (−2.2 to −3.9) (p <
0.001)
4 months: 15.9 ± 0.6;
−12.3 (−8.4 to −16.2) (p <
0.001)
6 months: 14.7 ± 0.6;

















































Pre: 19.7 ± 0.8
1 month: 16.1 ± 1.0;
−3.6 (−0.7 to −6.5) (p <
0.001)
3 months: 15.0 ± 0.8;
−4.7 (−2.1 to −7.2) (p <
0.001)
4 months: 15.9 ± 0.8;
−3.7 (−1.1 to −6.4) (p <
0.001)
6 months: 16.6 ± 0.8;
−3.0 (1.0 to −6.2) (p = 063)
G1 vs. G2
1 month: (p > 05)
3 months: (p > 05)
4 months: (p < 01)
6 months: (p < 0.001)
G1 vs. G2
1 month: (p > 05)
3 months: (p > 05)
4 months: (p < 0.001)














Pre: 5.5 ± 3.2
2 weeks: 2.8 ± 1.9 (p
< 0167)
6 weeks: 2.0 ± 2.2 (p
< 0167) vs. pre and
post.
G2
Pre: 5.4 ± 2.5
2 weeks: 2.9 ± 2.4 (p
< 0167)
6 weeks: 2.1 ± 2.3 (p
< 0167) vs. pre.
G3
Pre: 5.0 ± 2.5
2 weeks: 2.6 ±
2.1 (p < 0167)
6 weeks: 2.2 ±






1.9 ± 0.7 (p
< 0167)
6 weeks:




Pre: 3.1 ± 0.8
2 weeks: 2.1
± 0.7 (p <
0167)
6 weeks: 2.1






2.2 ± 0.8 (p
< 0167)
6 weeks:







1.8 ± 0.7 (p
< 0167)
6 weeks:







1.9 ± 0.8 (p
< 0167)
6 weeks:







1.9 ± 0.6 (p
< 0167)
6 weeks:
1.9 ± 0.7 (p
< 0167) vs.
pre.
Pre: p = 0.730
2 weeks: p = 0.860
6 weeks: p = 0.850
Pre: p = 0.380; 2 weeks: p = 0.600; 6 weeks: p
= 0.430
Pre: p = 0.910; 2 weeks: p = 0.580; 6 weeks:
p = 0.260
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Pre: 5.4 ± 2.1
1 week: 2.5 ± 1.4
−2.9 ± 1.1 (2.4–3.4).
4 weeks: 2.2 ± 1.5
−3.2 ± 1.1 (2.6–3.7).
8 week: 1.8 ± 1.2
−3.6 ± 1.6 (2.8–4.4).
12 weeks: 1.1 ± 0.8
−4.2 ± 2.1 (3.2–5.2).
G2
Pre: 5.0 ± 1.5
1 week: 3.9 ± 1.1
−1.1 ± 1.2 (0.5–1.7).
4 weeks: 3.4 ± 1.
−1.6 ± 1.4 (0.9–2.2)
8 week: 3.2 ± 1.1
−1.8 ± 1.5 (1.0–2.5)
12 weeks: -2.0 ± 1.8
(1.1–2.9)
G1 vs. G2
Pre: (p = 552)
1 week: (p =
0.002)
4 weeks: (p =
013)
8 week: (p <
0.001)
12 weeks: (p <
0.001)
G1
Pre: 33.4 ± 6.4
1 week: 21.7 ± 7.3
−11.7 ± 4.7 (9.4–14.1).
4 weeks: 19.6 ± 4.8
−13.9 ± 5.1 (11.3–16.4).
8 week: 17.1 ± 3.6
−16.3 ± 6.3 (13.2–19.4).
12 weeks: 13.7 ± 2.1














































Pre: 23.2 ± 6.2
1 week: 16.3 ± 6.9
−6.9 ± 6.3 (3.8–10)
4 weeks: 14.6 ± 4.9
−8.6 ± 6.8 (5.2–11.9)
8 week: 14.4 ± 5.0
−8.8 ± 7.0 (5.3–12.2)
12 weeks: 13.9 ± 5.0
−9.3 ± 7.4 (5.6–13.0)
G1 vs. G2
Pre: (p = 837)
1 week: (p = 077)
4 weeks: (p = 037)
8 week: (p = 0.004)
12 weeks: (p < 0.001)
G1 vs. G2
Pre: (p = 948)
1 week: (p = 032)
4 weeks: (p = 025)
8 week: (p = 016)
12 weeks: (p = 0.001)
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Pre: 4.38 ± 2.62
1 week: 18 (20.0)
–0.22 (–0.68 to 0.23)
2 weeks: 21 (23.3)
–0.30 (–0.81 to 0.21)
5 week: 27 (31.0)
–0.68 (–1.18 to –0.19)
17 weeks: 34 (40.0)
–1.22 (–1.79 to –0.65)
G2
Pre: 4.52 ± 2.78
1 week: 20 (22.0)
–0.43 (–0.89 to 0.04)
2 weeks: 24 (26.4)
–0.50 (–1.01 to 0.01)
5 week: 28 (31.1)
−0.55 (–1.11 to 0.02)
17 weeks: 31 (34.8)
–0.61 (–1.22 to 0.00)
G1 vs. G2
1 week: (p = 6)
4 weeks: (p = 7)
8 week: (p = 6)
12 weeks: (p =
03)
G1
Pre: 2.32 ± 0.62
1 week: 11 (12.2)
0.04 (–0.03 to 0.12)
2 weeks: 19 (21.1)
–0.01 (–0.09 to 0.07)
5 week: 33 (37.9)
0.17 (–0.28 to –0.06)
17 weeks: 40 (47.1)








































Pre: 4.52 ± 2.78
1 week: 17 (18.7)
0.09 (0.00 to 0.18)
2 weeks: 15 (16.5)
0.07 (–0.04 to 0.17)
5 week: 18 (20.0)
0.06 (–0.07 to 0.18)
17 weeks: 21 (23.6)
0.02 (–0.13 to 0.17)
G1 vs. G2
1 week: 0.02 (–0.09 to 0.13) (p = 8)
4 weeks: –0.01 (–0.13 to 0.11) (p = 9)
8 week:–0.15 (–0.29 to –0.01) (p = 0.04)
12 weeks: –0.20 (–0.36 to –0.03) (p = 02)
G1 vs. G2
1 week: 0.05 (–0.08 to 0.17) (p = 03)
4 weeks: 0.03 (–0.12 to 0.17) (p = 1.0)
8 week: –0.09 (–0.24 to 0.06) (p = 8)
12 weeks: –0.22 (–0.38 to –0.05) (p = 09)
Fusakul
(2014)
G1. Diode laser +
Splint




Pre: 6.26 ± 0.27 (p <
0.05)
5 weeks: 4.25 ± 0.34
(p < 0.05)
12 weeks: 3.45 ±
0.38 (p < 0.05)
G2
Pre: 4.83 ± 0.33 (p <
0.05)
5 weeks: 3.15 ± 0.30
(p < 0.05)
12 weeks: 2.48 ± 0.36
(p < 0.05)
G1 vs. G2
Pre: p = 0.174
5 weeks: p =
0.243
12 weeks: p =
0.433
G1
Pre: 2.10 ± 0.68 (p < 0.05)
5 weeks: 1.68 ± 0.66 (p <
0.05)























Pre: 1.77 ± 0.62 (p < 0.05)
5 weeks: 1.54 ± 0.62 (p <
0.05)
12 weeks: 1.37 ± 0.49 (p <
0.05)
G1 vs. G2
Pre: p = 0.291
5 weeks: p = 0.031
12 weeks p = 0.886
G1 vs. G2
Pre: p = 0.712
5 weeks: p = 0.406
12 weeks: p = 0.313
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3 weeks: 1 (0–5) p <
0.001














3 weeks: 5 (1–9) p
< 0.001
12 weeks:5 (0–9) p
= 085
G1 vs. G2
0–3 w: p = 879
0–12w: p = 879
G1 vs. G3







































































3 weeks: 2 (0–8) p <
0.001
















12 weeks: 7 (0–10)
p = 273
G1 vs. G2
0–3w: p = 245
0–12w: p = 577
G1 vs. G3






































































1.70 ± 0.57 vs. 1.54 ± 0.48
G1 vs. G2
0.11 (−0.10 to 0.33). p = 0.295
G1 vs. G2
0.05 (−0.16 to 0.25). p = 0.663
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shock waves + Splint




Pre: 6.26 ± 0.27
1 week: 3.15 ±
0.98 p < 0.01)
4 weeks: 2.48 ±
1.00 (p < 0.01)
8 weeks: 2.77 ±
1.37 (p < 0.01)
12 weeks: 2.70 ±
1.23 (p < 0.01)
G2
Pre: 5.90 ± 1.22
1 week: 4.47 ± 1.05 (p < 0.05)
4 weeks: 4.12 ± 1.14 (p < 0.05)
8 weeks: 3.80 ± 1.35 (p < 0.05)
12 weeks: 3.59 ± 1.27 (p < 0.05)
G1 vs. G2
1 week: p < 0.001
4 weeks: p < 0.001
8 weeks: p = 0.003
12 weeks: p =
0.006
G1
Pre: 32.65 ± 7.86
1 week: 20.20 ± 5.0 (p <
0.001)
4 weeks: 18.90 ± 4.76 (p <
0.001)
8 weeks: 17.50 ± 4.11 (p <
0.001)











































Pre: 16.65 ± 5.03
1 week: 14.30 ± 4.46
(p = 0.021)
4 weeks: 13.70 ± 4.84
(p < 0.019)
8 weeks: 13.95 ± 5.48
(p = 0.109)
12 weeks: 13.50 ± 5.77
(p = 0.107)
G1 vs. G2
1 week: p = 0.017
4 weeks: p = 0.005
8 weeks: p = 0.008
12 weeks: p = 0.171
G1 vs. G2
1 week: p= 0.001
4 weeks: p= 0.002
8 weeks: p= 0.002





G1. Unciform and scaphoid





Post vs. Post: p < 0.001
5.44 ± 2.35 vs. 1.94 ± 1.34
G2
Post vs. Post: p < 0.001
6.36 ± 1.16 vs. 3.52 ± 2.06
G1
Post vs. Post: p < 0.001


















Post vs. Post: p < 0.001
2.61 ± 0.57 vs. 1.76 ±
0.45
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G1. Kinesio-tape + Gliding
exercises
G2. Placebo kinesio-tape +
Gliding exercises




Post vs. Post: p =
0.005





5.8 ± 3.2 vs.
3.9 ± 2.8
G3
Post vs. Post: p =
0.024
6.1 ± 2.9 vs. 5.7
± 3.1























































Pre vs. Post: p =
0.003
3 (0–8) vs. 0 (0–8)
G2
Pre vs. Post: p = 0.011
5 (0–7) vs. 1 (0–7)
G1 vs. G2
−2 (−7;2) vs. -3
(−7;4): p = 0.53
G1
Pre vs. Post: p < 0.001


















Pre vs. Post: p = 0.57
19 (9–35) vs. 19 (8–29)
VAS night
G1
Pre vs. Post: p <
0.001
6 (1–8) vs. 0 (0–8)
G2
Pre vs. Post: p = 0.001
5 (0–9) vs. 0 (0–8)
G1 vs. G2
−5 (−8;2) vs. -4
(−8;2): p = 0.14
G1 vs. G2
−12.5 (−26;5) vs. −8.0 (−23;5): p = 0.39
G1 vs. G2
-5.5 (−18;2) vs. 0 (−11;5): p = 0.01
Hadianfard
(2015)
G1. Acupuncture + Night
splint




Post vs. Post: p <
0.001
7.32 ± 0.94 vs. 3.8
± 0.78
G2
Post vs. Post: p < 0.001




Post vs. Post: p < 0.001

















Post vs. Post: p < 0.001
18.00 ± 3.00 vs. 12.840
± 1.929
G1 vs. G2 p < 0.001 G1 vs. G2 p < 0.001
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Pre: 4.17 ± 2.23
1 month: 1.22 ±
1.59 p < 05
6 months: 1.06 ±
1.75 p < 05
G2
Pre: 3.17 ± 2.49
1 month: 2.97 ± 2.44 p > 05











to 0.4) p = 14
G1
Pre: 3.17 ± 0.86
1 month: 2.04 ± 0.68 p < 05

























Pre: 2.63 ± 0.84
1 month: 2.17 ± 0.97 p
< 05




Pre: 7.52 ± 2.57
1 month: 3.17 ±
2.59 p < 05
6 months: 2.88 ±
3.39 p < 05
G2
Pre: 7.07 ± 2.19
1 month: 5.10 ± 2.81 p < 05











to 0.1) p = 06
G1 vs. G2
Pre: 0.46 (0.01 to 0.9) p = 0.05
1 month: −0.13 (-0.5 to 0.3) p = 0.53
6 months: −0.24 (-0.7 to 0.2) p = 0.24
G1 vs. G2
Pre: 0.17 (−0.3 to 0.7) p = 48
1 month: −0.09 (−0.6 to 0.4) p = 73




G1. Tendon gliding exercises +
Paraffin + Night splint
G2. Nerve gliding exercises +
Paraffin + Night splint
G3. Paraffin + Night splint
VAS
G1







Pre vs. Post: p <
05
−17.2 ± 26.2


































G1 vs. G2 vs. G3 p = 56 G1 vs. G2 vs. G3 p = 04
Ordahan
(2017)
G1. Paraffin + Splint + Exercises
G2. Splint + Exercises
VAS
G1
Pre vs. Post: p =
0.009
7.31 ± 1.41 vs. 3.73
± 1.19
G2
Pre vs. Post: p = 0.013
6.95 ± 1.60 vs. 3.80 ± 1.67
G1 vs. G2 p =
423
G1
Pre vs. Post: p = 011


















Pre vs. Post: p = 214
2.41 ± 0.83 vs. 2.42 ±
1.05
G1 vs. G2 p = 0.551 G1 vs. G2 p = 0.021
Int. J. Environ. Res. Public Health 2021, 18, 2365 23 of 34
Table 4. Cont.















7.6 ± 0.7 vs. 5.8 ± 0.8





















25.8 ± 8.7 vs. 19.4 ±
6.4










Pre: 2.4 ± 2.5
1 week: 1.3 ± 2.0
(p < 0.18)
4 weeks: 1.3 ±
1.9 (p < 0.15)
12 weeks: 0.65 ±
1.2 (p < 0.022)
24 weeks: 0.35 ±
0.81 (p < 0.0075)
G2
Pre: 2.6 ± 2.0
1 week: 1.6 ± 1.7 (p < 0.08)
4 weeks: 1.3 ± 1.5 (p < 0.08)
12 weeks: 1.9 ± 2.7 (p < 0.52)
24 weeks: 1.7 ± 2.1 (p < 0.19)
G1 vs. G2
Pre vs. 1w: −10
(−1.7 to 1.5) p =
90
1w vs. 4w: 0.049
(−1.6 to 1.7) p =
95
4w vs. 12w: −1.0




0.49) p = 17
G1
Pre: 21 ± 6.4
1 week: 19 ± 7.4(p = 33)
4 weeks: 17 ± 4.3 p = 031)
12 weeks: 15 ± 4.5 (p =
0.0082)




































Pre: 12 ± 4.1
1 week: 11 ± 3.2 (p =
31)
4 weeks: 11 ± 3.3 (p =
39)
12 weeks: 10 ± 3.4 (p
= 19)
24 weeks: 13 ± 7.0 (p
= 65)
G1 vs. G2
Pre vs. 1w: 2.6 (−2.0 to 7.2) p = 27
1w vs. 4w: 1.5 (−3.2 to 6.1) p = 53
4w vs. 12w: −1.9 (−2.7 to 2.8) p = 43
12w vs. 24w: −5.1 (−9.8 to −33) p =
036
G1 vs. G2
Pre vs. 1w: 0.43 (−3.1 to 3.9) p = 81
1w vs. 4w: −20 (−3.7 to 3.3) p = 91
4w vs. 12w: −1.8 (−5.3 to 1.7) p =
32




G1. Short wave diathermy +
Gliding exercises




Pre vs. Post: p <
0.001
5.50 ± 2.53 vs.
2.32 ± 1.80
G2
Pre vs. Post: p = 1.105
4.83 ± 2.76 vs. 4.20 ± 2.53
G1 vs. G2 p =
0.003
G1
Pre vs. Post: p < 0.001



















Pre vs. Post: p = 234
28.8 ± 5.4 vs. 22.1 ±
6.5
G1 vs. G2 p = 0.002 G1 vs. G2 p < 0.001
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Pre vs. Post: p = 0.000
7.08 ± 1.56 vs. 3.75 ± 2.22
G2
Pre vs. Post: p = 0.000
6.58 ± 1.37 vs. 4.4 1 ± 1.31
G1 vs. G2 p = 141
G1
Pre vs. Post: p = 0.000



















Pre vs. Post: p = 0.008
4.83 ± 2.76 vs. 4.20 ±
2.53










Pre vs. Post: p < 01
5.72 ± 1.49 vs. 1.47 ± 1.20
G2
Pre vs. Post: p < 01
5.25 ± 1.75 vs. 3.58 ± 1.93
G1 vs. G2 p < 01
G1
Pre vs. Post:


















2.77 ± 0.94 vs. 2.55 ±
0.95








5.86 ± 1.46 vs. 1.38 ± 0.72
G2
Pre vs. Post:
5.71 ± 1.34 vs. 5.46 ± 1.05






















2.99 ± 0.67 vs. 2.87 ±
0.71









Pre: 2.5 ± 0.3
3 week: 1.4 ± 0.9(p = 0.04)
9 weeks:8 ± 1.1 (p = 0.02)
12 weeks: 0.6 ± 0.7 (p = 0.00)
G2
Pre: 2.6 ± 0.4
3 week: 1.5 ± 1.1(p = 0.04)
9 weeks: 1.7 ± 0.7 (p = 0.21)
12 weeks: 1.9 ± 1.3 (p = 0.17)
G1 vs. G2
3 week: p = 56
9 weeks: p = 0.00
12 weeks p = 0.00
G1
Pre: 34.1 ± 4.3
3 week: 30.2 ± 3.7 (p = 0.04)
9 weeks: 25.4 ± 4.1 (p = 0.01)
12 weeks: 22.3 ± 2.7 (p = 0.00)
G2
Pre: 34.7 ± 5.6
3 week: 28.1 ± 6.7 (p = 0.03)
9 weeks: 28.9 ± 6.8 (p = 0.05)
12 weeks: 31.8 ± 3.4 (p = 53)
G1 vs. G2–3 week: p = 43; 9 weeks: p = 0.00; 12 weeks p = 0.00
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G1: Ultrasound + Gel
with ketoprofen +
Splint
G2: Ultrasound + Gel





Pre: 5.76 ± 2.45
2weeks: 2.72 ± 2.07









Pre: 2.5 ± 0.3
2weeks: 3.03 ±
1.96
8 weeks: 0.98 ±
1.65
G1 < G3 p = 0.002
































































Pre vs. Post: p = 049




6.12 ± 1.54 vs. 4.79 ± 2.36
G1 vs. G2 p <
0.001
G1
Pre vs. Post: p < 0.001
2.20 ± 0.48 vs. 1.59 ± 0.29
G2
Pre vs. Post: p < 0.001
2.18 ± 0.49 vs. 1.78 ± 0.53
G1 vs. G2 p = 0.003
BCTQ: Boston Carpal Tunnel Questionnaire; BCTQ-SSS: BCTQ Symptom Severity Scale; BCTQ-FSS: BCTQ Function Severity Scale; NPRS: Numeric Pain Rating Scale; VAS: visual analogue scale.
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Regarding pharmacological treatment, the studies compared a type of corticosteroids
with other drugs or with placebos. There were no statistically significant conclusions as
to their effectiveness. The studies that analyzed using platelet-rich plasma did not reveal
significant differences [33,34]. Combining corticosteroids and night splints presented
statistically significant improvements compared with using solely drugs or night splints.
Electrotherapy presented statistically significant improvements over corticosteroids [47].
The most often used drugs were triamcinolone, lidocaine and methylprednisolone. One
dose of 5% dextrose was statistically significant compared to placebo or triamcinolone.
Concerning electrotherapy, all the outcomes showed statistically significant improve-
ments in pain and/or function (BCQT) against placebo or control groups. Most of these
studies added a night splint as part of the treatment. In isolation, electrotherapy was
not as effective compared with the control and/or placebo groups. The therapies used
were shock waves [21,24,47], ultrasound [37,48], laser [38,39], electro-acupuncture [25,41],
diathermy [40] and radiofrequency [22].
As far as manual therapy is concerned, the articles presented significantly better im-
provements in these groups in functional variables (BCQT), and some, in symptoms and
strength. These studies were the main ones obtaining changes in the electrophysiological
parameters. The studies that compared manual therapy and electrotherapy found signifi-
cant differences in favor of the manual therapy group [23,30]. The interventions featured
the use of neurodynamic techniques [26,27,45], acupuncture [28,44], exercise [50], joint
mobilization [43,46] or a combination of various techniques [23,30,42]. Nerve mobilization
or neurodynamic techniques were described differently among the studies. Three studies
included mobilization from shoulder to fingers, described by Shacklock [23,30,45] as initial
position; shoulder abduction to 90◦; arm external rotation; wrist and fingers extension;
forearm supination; and elbow extension, compared to those who performed only wrist
and hand mobilization [27,40] in six different positions as grasping, finger extension, wrist
extension, thumb extension, forearm supination, and gentle stretch of the thumb with the
opposite hand. Joint mobilization consisted in performing distraction and dorsal/palmar
glides on the first row of the radiocarpal joints [43] or dorsal and palmar glide on scaphoid
and hamate bones [46]. Both studies aimed to improve wrist range of motion on CTS
patients. In addition, treatment of soft tissue was complementary to other manual tech-
niques. Acupuncture techniques were described in isolation. Both studies followed a
similar protocol, involving described acupoints unilaterally for the involved side. Hadi-
anfard et al. [44] include nine acupoints compared to Tezel et al. [28] that performed the
therapy on six acupoints. Functional massage (a combination of muscle compression while
mobilizing the joint) of the soft tissue was performed in two studies, complementary to
other manual therapy treatment. Talebi et al. [23] performed it on pronator teres muscle,
unlike Wolny et al. [30] who performed it on the trapezius muscle. Both techniques were
not described.
Lastly, lavender ointment combined with a night splint did not yield any significant
differences compared with the placebo groups [49]. Lavender ointment and placebo were
instructed to be applied on their affected wrist in the morning and evening time for 40 days.
3.2.3. Variables
All the studies included assessed function using the BCTQ scale, and 3 added the
DASH questionnaire on shoulder, elbow and hand impairment [25–27]. All the articles
evaluated pain, with 25 using a visual analogic scale (VAS) and 4 using the numeric pain
rating scale (NPRS) [25,26,43,45]. In addition to the evaluation of pain, 3 articles used a
VAS to quantify paresthesia [21,34,37].
Twenty articles analyzed electrophysiological parameters, 12 articles analyzed grip
strength and/or pinch strength [21,22,25,26,32,37,39,42,43,45] and 6 articles analyzed the
cross sectional area of the carpal tunnel using a ultrasound-guided
procedure [21,22,29,34,36,37]. Other variables measured were quality of life (Notting-
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ham Health Profile [NHP] and World Health Organization Quality of Life [WHOQOL]),
neurodynamic tests, range of movement, or clinical parameters (Tinel and Phalen tests).
3.2.4. Follow-Up
Most studies had a follow-up of no more than 6 months, with the majority of the
studies having short- and mid-term follow-ups. There were 24 articles that studied the
short-term (≤3 months) effects, while 5 had mid-term (≤6 months) follow-ups. The studies
analyzing drug application mainly analyzed mild term follow-ups.
3.2.5. Evaluation of the Risk of Bias
The methodological quality scores ranged from 6 to 10. The mean quality of all the
studies analyzed by the PEDro scale [19] was 7.5 over 11. 14 of the 29 studies obtained a
score of 8 or more on this scale (Table 5). The blinding of the participants of the samples, the
blinding of the researcher who carried out the therapy were the criteria with no achievement
throughout the studies. Moreover, the criterion of “all subject for whom outcome were
available received the treatment or control condition as allocated or, where this was not the
case, data for at least one key outcome was analyzed by intention to treat” was less achieve
by the studies.
Table 5. PEDro Scale.
Study 1 2 3 4 5 6 7 8 9 10 11 Total
Atthakomol
(2018) X X X X X X X 7
Çatalbas (2018) X X X X X X X 7
Chen (2015) X X X X X X X 7
Chung (2016) X X X X X X X X X X 10
Dinarvand (2017) X X X X X X 6
Eftekharsadat
(2018) X X X X X X X X 8
Fusakul (2014) X X X X X X X X 8
Geler-Külcü
(2016) X X X X X X X X 8
Günay (2015) X X X X X X X 7
Güner (2018) X X X X X X X 7
Hadianfard (2015) X X X X X X X X 8
Hamzeh (2020) X X X X X X X 7
Horng (2011) X X X X X X 6
Incebiyik (2015) X X X X X X X X 8
Karimzadeh
(2019) X X X X X X 7
Kumnerddee
(2010) X X X X X X 6
Ordahan (2017) X X X X X X 6
Raeissadat (2018) X X X X X X X X 8
Senna (2019) X X X X X X X X 8
Talebi (2018) X X X X X X X X 8
Tezel (2019) X X X X X X 6
Wang (2017) X X X X X X X X X 9
Wolny (2019) X X X X X X 6
Wolny (2017) X X X X X X X 7
Wu (2018) X X X X X X X X 8
Wu (2017) X X X X X X X X X 9
Wu (2016) X X X X X X X X X 9
Xu (2020) X X X X X X X X 8
Yildiz (2011) X X X X X X X X 8
Mean 7.5
The RoB2 tools [20] showed that the aspects with the worst methodological quality
in all the studies are found in the effect of assigning to the intervention and the results
reported. Variable measurement seems to have the best methodical quality in all the studies
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considered (Figure 2a,b). Even though, it seems that good methodological quality was
performed in the majority of studies.
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4. Discussion
Our study objective was to review the effectiveness of conservative treatment in
patients with CTS of any level of severity, with the inclusion of patients with systemic con-
ditions. In patients having mild or moderate intensity, three types of treatment were used:
drug, electrotherapy and manual therapy. Severe patients were not analyzed isolated, not
allowing which kind of treatment is effective for them. Patients with systemic disease were
poorly represent in samples. Two studies include patients with diabetes and hypertension,
and another analyzed aa sample of diabetic patients. Manual therapy could be effective for
those patients at short-term, but more future studies have to be done.
Splint therapy was the more used control or complementary intervention. Adding
a wrist splint to all kind of intervention treatments seem to be more beneficial than not
including the orthosis. Hall et al. [51] observed that conservative treatment program
including full-time splinting and formal education can improve symptoms and function
on CTS patients. It could be considered for symptom reduction in all patients waiting
for the surgical intervention. Burke et al. [52] observed the angle of the splint does make
a difference in subjective relief of the symptoms of carpal tunnel syndrome, and that
this difference is apparent after wearing the splints for only two weeks. They prove that
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the neutral angle wrist splint will provide better symptom relief than the traditional 20◦
extension wrist splint or even in flexion. Even though, a customized orthosis should be the
best option for the most effective treatment of the patient’s symptoms.
Within the pharmacological treatment, using local corticosteroids, as methylpred-
nisolone, was common. Oral corticosteroids reduce oedema, improving the space between
the carpal tunnel and the median nerve [5]. It shows to have strong evidence to improve
reported patients outcome [53]. Solely a greater dose of corticosteroids was found to be
statistically significant for function after three months [32]. However, it was not more effec-
tive than shock waves after 24 weeks [24], or than a 5% dextrose solution after 6 months, at
the level of symptoms and function [36]. Its effect was more beneficial combined with a
splint therapy than solely with a splint after 12 weeks, at the level of function, symptoms
and electrophysiological parameters [54], with a fairly good quality of studies. Injection of
dextrose is a new treatment for peripheral neuropathies, because it possesses osmolarity
similar to that of normal saline, and no harmful effects have been reported from animal
and human studies [55]. Furthermore, one dose of 5% dextrose showed to be effective to
improve function and CTS symptoms. Similar to a glucose molecule, the mechanism of
an injection of hypo-osmolar 5% dextrose postulated induced analgesic effect on tender
peripheral nerves as well as central nerve system by osmotic rupture of local cells [56,57].
Another treatment growing in popularity is injecting platelet-rich plasma. This is used
as an alternative to surgery because of the regenerative effect it can produce in patients
with demyelination and axonal degeneration in CTS [48]. Platelet-rich plasma seems to
be more effective three months after the injection at the level of symptoms, function and
electrophysiological and clinical parameters than methylprednisolone injection [34]. How-
ever, there are no evidences indicating that it is more effective than night splinting after
10 weeks of treatment [33].
Considering electrotherapy, few studies assessed its effectiveness during its isolated
application rather than combined with other type of therapies (manual therapy, splint,
bandaging). This makes it difficult to evaluate the effectiveness of electrotherapy alone.
Electro-acupuncture was the only treatment compared alone with night splinting; it ob-
tained superior improvements in pain following five weeks of treatment compared with
splinting [41]. However, the quality of the study was moderate. Low-power laser combined
with bandaging [39], the use of diathermy and nerve gliding exercises [40] and ultrasound
with ketoprofen gel and night splinting [48] presented better improvements in symptoms
and function following treatment than these procedures alone or compared with placebo.
Focusing on manual therapy, all the techniques were assessed in combination or with
other types of treatment (splints, bandages, diathermy, exercises). It seems that carpal
bone mobilizations combined with night splinting are more effective after treatment at
the level of function and symptoms than splinting alone. However, the methodological
quality of these studies was moderate. It also seems that neurodynamic techniques used
alone improve electrophysiological variables of function and symptoms compared with a
control group, with moderate methodological quality [28]. Furthermore, neurodynamic
techniques combined with other therapy, soft tissue or joint mobilization was more effective
in symptoms and function following treatment than the combination of transcutaneous
electrical nerve stimulation (TENS) and ultrasound or laser and ultrasound [30]; following
treatment, acupuncture combined with splinting seems to be more effective for symptoms
than splinting alone or combined with ibuprofen [28,44]. Acupuncture plus splinting also
improved electrophysiological variables and function, in a study having good methodologi-
cal quality [44]. Following treatment, paraffin combined with splinting and exercises seems
to have a positive effect on function and electrophysiological parameters, but the study
had moderate methodological quality [50]. All these treatments seem to have short term
treatment effects, but few studies assessed their mid or long-term effect. Consequently,
their effect on resolving CTS cannot be established.
The variability while performing the different manual techniques between studies
can explain the diversity of results. Firstly, there is a lack of terminology consensus or
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standardization in the techniques whose aim is to mobilize the nervous system. Moreover,
parameters such as the mobilization dosages, the number of joints to be mobilized and
the consideration to stabilize or not the wrist joint while performing the gliding mobiliza-
tion techniques are not uniform throughout the studies. Shacklock (2005) considers the
stabilization of the related joint to the nerve region to be mobilized important to achieve a
specific mobilization. On the other hand, joint mobilization aims to improve wrist range of
motion. However, some joint mobilizations [58], described as transverse and ventral glide
on dorsal side of the first carpal row, have been designed to release carpal tunnel syndrome,
increasing cross-sectional area of carpal tunnel. In addition, soft tissue mobilization aims to
reduce pressure on the carpal tunnel syndrome by improving the mobility of the myofascial
tissues adjacent to the nerve. More studies need to be carried out to see the most effective
combination of soft tissue and joint mobilization treatment in CTS patients.
Lavender oil is frequently used as an herbal medication for a wide variety of diseases,
either topically or by inhalation. In vivo studies have shown that the active ingredients of
lavender oil have important anti-inflammatory, anti-nociceptive, sedative, and analgesic
therapeutic potentials [59]. However, using lavender ointments combined with night
splints was not any more effective than a placebo ointment combined with splinting [49].
Results were only reported pre- and post-intervention, without follow-ups.
When severe patients were included, the isolated effect that conservative treatments
produce in these patients was not found. These patients with electrophysiological abnor-
malities could show thenar muscle atrophy, and more diffuse symptoms. Surgical approach
was the option of choice [5]. In some studies, electrotherapy was applied in mild, moderate
and severe cases. Combined with a night splint, it seemed effective for symptoms and
function following treatment; however, it is unclear whether these effects will be main-
tained at long-term [22,25]. In patients with severe CTS, other studies reported the effect of
manual therapy including nerve gliding exercises [26], tendon gliding exercises [27] and
acupuncture [28]. Both tendon and nerve gliding exercises improved function immediately
and six months after treatment but combined with paraffin [27] and splinting or an exercise
program [26]. Acupuncture reduced pain following treatment, once again combined with
night splinting [28]. The moderate quality of these studies and the combination with other
types of treatment make it difficult to establish the best effect of these therapies on the
more severe CTS cases. It would be interesting to report results stratifying level of CTS
severity to prove that conservative management it is a beneficial option for these patients.
Still, electrotherapy and manual therapy could be beneficial to severe CTS.
Diagnosis of CTS should be performed by physical examination and nerve conduc-
tion studies [53]. All the studies included in this review performed one or both items.
Electrophysiological studies were considered the gold standard to diagnose CTS patients.
These tests can define the degree of demyelination and axonal loss that has occurred.
Bland [60] scale described degrees to classify the severity of CTS as: Grade 0 denotes no
neurophysiological abnormality; Grade 1, very mild CTS, detected only in two sensitive
test; Grade 2, mild CTS as orthodromic sensory conduction velocity from index finger
<40m/s with motor terminal latency from wrist to abductor pollicis brevis (APB); Grade
3, moderately severe CTS as motor terminal latency >4.5 ms and <6.5 ms with preserved
index finger sensory nerve action potential (SNAP); Grade 4, severe CTS as motor terminal
latency >4.5 ms and <6.5 ms with absent SNAP; Grade 5, very severe CTS as motor terminal
latency >6.5 ms; and Grade 6, extremely severe CTS as surface motor potential from APB
<0.2 mV peak-to-peak. However, the American Association of Orthopedic Surgeon [61]
bundle this classification in mild (grade 1 and 2), moderate (grade 3) and severe (grade
4, 5, and 6), as reviewed studies performed. In the other hand, physical examination was
performed in all studies reviewed, nonetheless a variety of test was performed. Phalen
test, Tinel test and symptoms in neuroanatomical median nerve distribution were the most
performed. Similarly, to electrophysiological studies, the physical examination tends to test
the myelinated fiber function. Nowadays, this criterion should be disputed due to negative
electrophysiological parameters in presence of CTS or symptoms beyond neuroanatomical
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distribution [7]. A new approach proposed to include the assessment of small nerve fibers
or unmyelinated nerve fibers such as quantitative sensory testing to help confirming the
presence of CTS [62]. This includes assessment of heat, cold and vibration sensation thresh-
olds to evaluate nerve fibers that are not tested during nerve electrophysiological studies.
Besides, combination of all these items must be taken into consideration in order to make a
correct diagnosis, relating it to the patient’s clinical history.
Another point is that, although CTS is generally idiopathic, some conditions such
as diabetes or hypertension predispose individuals to suffer from neuropathy. In these
patients, the risk of suffering CTS is three times greater than in healthy patients [63].
However, in studies including patients with hypertension and/or diabetes (only 3 of 29),
they only represented from 5% to 20% of all the patients evaluated [21,22]. Consequently,
the direct effect of electrotherapy in patients with hypertensions and/or diabetes cannot be
established. There was only a single study in the review [23] that studied patients with
diabetes and CTS. It was found that, after four weeks of treatment, manual therapy (soft
tissue and nerve mobilization) seemed more effective than the use of TENS and ultrasound
on function, symptoms and neurodynamic results. However, this study did not present
long-term results and its methodological quality was only moderate. Assessing small fibers
nerve could help therapist to perform a more comprehensive approach on patients with
both CTS and systemic condition. Even though, a combined protocol of manual techniques
could be more effective for diabetic patients with CTS than electrotherapy in the short term.
We believe that there is insufficient research on CTS in patients with systemic pathol-
ogy. There is a lack of representation of CTS patients with diabetes in the studies given their
high prevalence and the possibility of developing CTS throughout their lives. Moreover,
the conservative approach should be more studied in this subgroup as it can be more
difficult to diagnose CTS in patients with diabetes because the earliest symptoms can be
mistaken for diabetic polyneuropathy [64], and controversy exists about surgical treatment
for these patients [65]. Given the lack of representation of patients with CTS and systemic
diseases in the studies dealing with conservative therapy approaches, we consider this type
of patients should be included in the sample selection criteria in studies on conservative
treatment for CTS. This would help to ascertain the effect of conservative treatment in more
representative CTS samples.
There are some limitations in this review that arise from the biases found in the articles.
The lack of uniformity in the sample selection criteria makes it difficult to compare data
among them. The variability of techniques proposed, and their combinations do not permit
accurate comparison of their effectiveness either.
The lack of uniformity in methodological quality also hinders accurately evaluating
treatment effectiveness. In addition, there might be references in other language besides
Spanish, English and French that were not considered due to the language restrictions estab-
lished in our selection criteria. More reviews should be performed performing quantitative
analysis to prove specific results.
5. Conclusions
In patients with mild and moderate CTS, electrotherapy seems to be effective following
treatment as long as it is combined with splinting, but its effectiveness is no greater than
manual therapy. Corticosteroid injection does not appear to be more effective than saline
solution or other techniques such as electrotherapy or manual therapy. No conclusions
can be reached on the effectiveness of platelet-rich plasma to treat CTS; further studies
are needed. One injection of 5% dextrose seems to be effective for CTS symptoms and
function. Wrist splint could be useful to complement treatments, however wrist position
should be described in future studies, taking into account the position that best relieves
patient’s symptoms. Electrotherapy and manual therapy could be beneficial for severe
CTS, and manual therapy for diabetic CTS in the short term. However, the specific effect of
conservative treatment should be established with a stratification analysis depending on
the intensity level of CTS. More long-term studies need to be carried out to specify which
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treatment is most beneficial for which type of severity. It seems that some pharmacological
treatments, manual therapy and electrotherapy have benefits for handling CTS, although
the most effective combination of techniques is unknown. However, it does seem that a
combined treatment for each patient might be the most effective option.
A final point is that patients with systemic conditions and severe CTS should be
included in the inclusion criteria for future CTS studies analyzing conservative approaches.
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